Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients With Advanced NSCLC With BRAF, HER2, or MET Mutations or RET Translocation: GFPC 01-2018.
Guisier F, Dubos-Arvis C, Viñas F, Doubre H, Ricordel C, Ropert S, Janicot H, Bernardi M, Fournel P, Lamy R, Pérol M, Dauba J, Gonzales G, Falchero L, Decroisette C, Assouline P, Chouaid C, Bylicki O.
Guisier F, et al. Among authors: ricordel c.
J Thorac Oncol. 2020 Apr;15(4):628-636. doi: 10.1016/j.jtho.2019.12.129. Epub 2020 Jan 13.
J Thorac Oncol. 2020.
PMID: 31945494
Free article.